ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
PLAUR	5329	11063652	-	Up regulation/ Over expression/High expression	-	-	16 (6 prolifeartive; 5 seceretory; 5 postmenopausal)	34 (30 postmenopausal+ 4 premenopausal)	-	-	Royal Women's Hospital	-	1 (n=13); 2 (n=11); 3 (n=10)	[1] uPAR is significantly elevated in all of the clinical stages of malignancy examined; with a 33-fold increase in mRNA expression from normal endometria to advanced clinical stage carcinomas (Stage III; P < 0.0001). The expression of uPAR mRNA also increased with each progression in clinical stage. [2] Expression of uPAR mRNA was significantly higher in all grades (Grade 1; P ; 0.05; Grade 2; P ; 0.001; Grade 3; P ; 0.001; Mann–Whitney U test; respectively) when compared to the normal group.	Differential mRNA expression of urokinase-type plasminogen activator; plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.	Gynecologic Oncology	79(2):244-50	2000
PLAUR	5329	12130664	Endometrioid adenocarcinoma+ Uterine Papillary Serous Carcinoma+ Mixed Malignant Mesodermal tumor)	-	Prognostic Marker	-	-	58 (40 endometrioid adenocarcinoma+ 12 uterine papillary serous carcinoma+ 6 mixed malignant mesodermal tumor)	-	-	Department of Pathology; University of California; Los Angeles	I (n=32); II (n=6); III (n=7); IV (n=13)	1 (n=21); 2 (n=2); 3 (n=8)	[1] UPAR protein expression also positively correlated with rate of recurrence and mortality in patients with adenocarcinoma of the endometrium (ungrouped P = 0.034). [2] UPAR protein expression highly correlated with stage of disease (ungrouped Spearman correlation = 0.625; P < 0.0001): 40% of patients with stage I; 66% of patients with stage II; 100% of patients with stage III; and 85% with stage IV demonstrated the highest level of UPAR expression. Moreover; high UPAR expression positively correlated with grade of disease (ungrouped Spearman correlation = 0.71; P < 0.0001): 29% of grade 1 specimens; 57% of grade 2; and over 90% of specimens with grade 3; the majority representing uterine papillary serous carcinoma and mixed malignant mesodermal tumor.	Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.	Proceedings of the National Academy of Sciences of the United States of America	99(16):10647-52	2002